Ramipril clinical pharmacology

Revision as of 16:27, 18 February 2014 by Amr Marawan (talk | contribs) (Created page with "__NOTOC__ {{Ramipril}} {{CMG}}; {{AE}} {{AM}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTACE (RAMIPRIL) CAPSULE [PFIZER LABORATORIES DIV P...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]

For patient information about Ramipril, click here.

Ramipril

Overview

Ramipril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.

Category

Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [4]; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [5]

[1]


References

  1. "ALTACE (RAMIPRIL) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC]".

Adapted from the FDA Package Insert.